Evaluation of the use of biomarker levels in dried blood spots as a measurement tool for disease severity in patients with atopic dermatitis and psoriasis.

Evaluation of the use of biomarker levels in dried blood spots as a measurement tool for disease severity in patients with atopic dermatitis and psoriasis. - Dried blood spots in atopic dermatitis and psoriasis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41918

Enrollment

140

Registered

2015-02-11

Start date

2015-04-13

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis atopic eczema eczema psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -over 18 years of age -diagnosis of AD (according to the criteria of Hanifin and Raijka) or diagnosis of psoriasis -treatment with topical steroids

Exclusion criteria

Exclusion criteria: Treatment with systemic corticosteroids or other immunosuppressive medication within the 4 weeks prior to obtaining the DBS.

Design outcomes

Primary

Measure	Time frame
- Levels of 7 biomarkers determined from DBS (three time points) - Disease severity measured by POEM / SA-PASI (patient). (three time points) - Disease severity measured by EASI / PASI (physician). (three time points)	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results